Multiple Clinical And Preclinical Presentations At ASH 2023 Highlight Vor Bio's Novel eHSC And CAR-T Platform
Portfolio Pulse from Benzinga Newsdesk
Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, announced that preclinical and clinical data supporting its novel platform for treating acute myeloid leukemia (AML) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. The data includes updates from the VBP101 clinical trial and the CD33CART Study. The company also released data from a single cell analysis studying molecular signatures from 28 AML patients and from a preclinical collaboration with Janssen. A trial-in-progress poster will be presented on the Company's VBP301 clinical trial.
November 02, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vor Bio's announcement of presenting preclinical and clinical data at the ASH Annual Meeting & Exposition could potentially boost investor confidence in the company's novel platform for treating AML.
The announcement of Vor Bio's presentations at the ASH Annual Meeting & Exposition indicates progress in the company's research and development efforts. This could potentially boost investor confidence in the company's novel platform for treating AML, leading to a positive short-term impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100